Possible Patent Typo Debated As Juno, Kite IP Trial Kicks Off

Law360, Los Angeles (December 3, 2019, 11:23 PM EST) -- Lawyers for Juno Therapeutics and Kite Pharma delivered opening statements Tuesday in Juno's infringement suit over its groundbreaking cancer immunotherapy — a potentially multibillion-dollar fight that may turn on whether a California federal jury believes Juno's patent contained a simple typo or not.

Morgan Chu of Irell & Manella LLP, who is representing Juno Therapeutics Inc., Memorial Sloan Kettering Cancer Center and Sloan Kettering Institute for Cancer Research, told the jury during openings that Kite Pharma Inc. willfully infringed his clients' patent in order beat Juno to the market.

But Kite's attorney Ted Dane of Munger Tolles & Olson LLP told...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS